Assessing individual head and neck squamous cell carcinoma patient response to therapy through integration of functional and genomic data

Even though head and neck squamous cell carcinoma (HNSCC) is the seventh most common cancer worldwide, there are only two PD-1 targeted immunotherapies (pembrolizumab and nivolumab) and one tumor intrinsic EGFR targeted therapy (cetuximab) that are FDA approved for treatment of HNSCC. Taking advanta...

Full description

Saved in:

Bibliographic Details
Published in:	Scientific reports Vol. 15; no. 1; pp. 19742 - 14
Main Authors:	Bottomly, Daniel, Mathieson, Chase, Vigoda, Myles, Jeng, Sophia, Evans, Nathaniel, Anderson, Ashley, Blucher, Aurora, Lesch, Aletha, Zheng, Christina, Laderas, Ted, Jacobs, James, Kulesz-Martin, Molly, McWeeney, Shannon
Format:	Journal Article
Language:	English
Published:	London Nature Publishing Group UK 05.06.2025 Nature Publishing Group Nature Portfolio
Subjects:	631/114 692/4028/67/1536 692/4028/67/69 Antitumor drug screening assays Cancer Cancer therapies Chemotherapy Copy number DNA Copy Number Variations Genes Genomics Genomics - methods Head and neck carcinoma Head and Neck Neoplasms - drug therapy Head and Neck Neoplasms - genetics HNSCC Humanities and Social Sciences Humans Immunotherapy Leukemia Multi-Omics multidisciplinary Mutation Patients PD-1 protein Pembrolizumab Precision Medicine Science Science (multidisciplinary) Squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck - drug therapy Squamous Cell Carcinoma of Head and Neck - genetics Squamous Cell Carcinoma of Head and Neck - pathology Tumors Multi-Omics Antitumor drug screening assays HNSCC
ISSN:	2045-2322, 2045-2322
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!